Dr. Stephen H. Tsang
Dr. Stephen H. Tsang, graduated from Johns Hopkins University, where he began his medical genetics training the Columbia by with are the embryonic stem (ES) cells to model and replace diseased human retinal cells in rod monochromatism and of University Professor in Ophthalmology”-“Research to Prevent Blindness” Award. Dr. Tsang also participates course director. He is a member of the Macular Society and an assistant professor at Columbia University.
Dr. András M. Komáromy
Dr. András M. Komáromy is a clinician scientist in the Department of Clinical Studiesat the University of Pennsylvania School of Veterinary Medicine in Philadelphia;joining as a post-doctoral fellow in 2003 and becoming an Assistant Professor in 2004.He received his veterinary degree from the University of Zurich in Switzerland, wasan intern in small animal medicine and surgery at the Michigan State University, andobtained his PhD and veterinary ophthalmology training at the University of Florida. Dr.Komáromy is a board-certified… CONTINUE READING >>
William W. Hauswirth, Ph.D.
Dr. Hauswirth received his B.S. in Chemistry from Stanford University and his Ph.D in PhysicalChemistry from Oregon State University. After an NIH Fellowship in the Biochemistry Department atJohns Hopkins University, he joined that department as an Assistant Professor. In 1976, he joined thefaculty of Molecular Genetics and in 1985 the Ophthalmology faculty at the University of Florida Collegeof Medicine. Before turning his attention to the retina, while at UF Dr. Hauswirth is, in part, responsible fordetermining the mechanism of… CONTINUE READING >>
Sue Washer
Sue Washer, President and CEO of AGTC, is an experienced entrepreneur with a strong scientific and operational background. She has a B.S. in biochemistry from Michigan State University and an MBA from the University of Florida where she was one of the first graduates from the Business Schools Entrepreneurship program. Sue has 10 years of pharmaceutical management and research experience from Abbott Labs and Eli Lilly as well as 11 years of senior management experience with entrepreneurial firms in the Gainesville area. Sue successfully raised over $15M for AGTC in their second round of funding in November of 2003.
Dr. Jeff Chulay
Chief Medical Officer and Vice President of Regulatory Affairs Dr. Chulay brings broad medical and regulatory expertise to the Company. He joined AGTC in 2007 from AlphaVax, where as Senior Vice President and Chief Medical Officer he led successful clinical trial programs of recombinant viral vector vaccines for cytomegalovirus and influenza. Prior to joining AlphaVax, Dr. Chulay was a Principal Clinical Program Head in HIV and Opportunistic Infections at GlaxoSmithKline and was responsible for bringing two anti-infective drugs to market. He previously served as Chief of the Department of Immunology at… CONTINUE READING >>
Dr. Richard L. Windsor
Dr. Laura Windsor
